DMT-2'-O-Me-A(Bz)-CE Phosphoramidite

N6-benzoyl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Adenosine-3'-CE-Phosphoramidite
Catalog No. PR1-001
CAS No. 110782-31-5
Purity HPLC ≥98.0%
Molecular Formula C48H54N7O8P
Molecular Weight 887.96
Storage Condition -20℃

DMT-2'-O-Me-A(Bz)-CE Phosphoramidite

N6-benzoyl-5'-O-(4, 4'-Dimethoxytrityl)-2'-O-methyl-Adenosine-3'-CE-Phosphoramidite
Grade
Amount/Package: 0.25g / 30mL screwed bottle-28
SKU: PR1-001-025A  |  suitable for  MerMade
Collections:  2'-O-Me Phosphoramidites Diagnostics Oligo Synthesis Phosphoramidites Phosphoramidites for Diagnostics Recommended Products Synthesis Blocks
Unit price:
$19.00
Price
$19.00
Taxes, discounts and Shipping calculated at checkout.
This variant is unavailable. Contact us if you have particular requirements.
Checkout

This Variant only supports customization. Please click the inquire button to submit a custom request.

Price/Order Inquiry

Shipping notes
Products on this site:
Currently ships to US and Canada.
For shipping worldwide, please contact us.
Order fulfillment: within 2 business days, if available.
US: 2-8 days (from CA by FedEx).
Canada: 5-10 days (excludes customs delays).

Related Products

    Details

    DMT-2'-O-Me-A(Bz)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a benzoyl (Bz) base-protecting group on adenine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

    The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

    Applications

    siRNA chemical modification

    Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

    Enzyme or structural RNA inhibition

    Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

    Features and Benefits

    Delivers high coupling efficiency and consistently strong crude yields
    Manufactured to ≥98% purity with tightly controlled impurity specifications
    Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
    Simplified purification: no special precautions needed against RNase degradation

    Other Notes

    • Storage: Store in a dry, inert atmosphere at -20 °C.
    • Coupling: 6 minute coupling time recommended
    • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
    • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

    Reference

    [1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

    Specifications
    • Catalog No.
      PR1-001
    • CAS No.
      110782-31-5
    • SMILES
      CC(C)N(C(C)C)P(OCCC#N)O[C@H]1[C@@H](OC)[C@H](N(C=N2)C3=C2C(NC(C4=CC=CC=C4)=O)=NC=N3)O[C@@H]1COC(C5=CC=C(OC)C=C5)(C6=CC=CC=C6)C7=CC=C(OC)C=C7
    • Molecular Formula
      C48H54N7O8P
    • Molecular Weight
      887.96
    • Appearance
      White to off-white powder, free from visible foreign matter
    • Purity
      HPLC ≥98.0%
    • Storage Condition
      -20℃
    • Moisture Content
      K.F.≤0.20% w/w

    Documentation
    COA Contact Us

    DMT-2'-O-Me-A(Bz)-CE Phosphoramidite is a 2'-OMe phosphoramidite monomer used for solid-phase oligonucleotide synthesis. It contains a 5'-dimethoxytrityl (DMT) protecting group for 5'-hydroxyl protection, a benzoyl (Bz) base-protecting group on adenine, a cyanoethyl (CE) protecting group on phosphite, and a 2'-O-methyl (2'-OMe) ribose modification

    The 2'-OMe modification improves duplex stability, reduces immunogenicity, and significantly increases resistance to nucleases

    Applications

    siRNA chemical modification

    Applied on siRNA duplexes to improve serum stability, reduce off-target effects, and modulate RISC loading.[1][2]

    Enzyme or structural RNA inhibition

    Inhibit specific RNAs or enzymes (e.g., telomerase) through binding interference.[4]

    Features and Benefits

    Delivers high coupling efficiency and consistently strong crude yields
    Manufactured to ≥98% purity with tightly controlled impurity specifications
    Compatible with standard phosphoramidites under routine solid-phase synthesis conditions
    Simplified purification: no special precautions needed against RNase degradation

    Other Notes

    • Storage: Store in a dry, inert atmosphere at -20 °C.
    • Coupling: 6 minute coupling time recommended
    • Recommended deprotection: 8 h at 55 °C in concentrated ammonia, or 10 min at 65 °C in AMA (ammonia/methylamine, 1:1 v/v)
    • Compatibility: Can be used alongside modified phosphoramidites (e.g., 2′-OMe, 2′-MOE, Locked-NA) to synthesize chimeric oligonucleotides.

    Reference

    [1] Chiu, Ya-Lin, and Tariq M. Rana. "siRNA function in RNAi: a chemical modification analysis." Rna 9, no. 9 (2003): 1034-1048. [2] Hu, Bo, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, and Xing-Jie Liang. "Therapeutic siRNA: state of the art." Signal transduction and targeted therapy 5, no. 1 (2020): 101. [3] Burmeister, P.E., Lewis, S.D., Silva, R.F., Preiss, J.R., Horwitz, L.R., Pendergrast, P.S., McCauley, T.G., Kurz, J.C., Epstein, D.M., Wilson, C. and Keefe, A.D., 2005. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chemistry & biology, 12(1), pp.25-33. [4] Pitts, Anne E., and David R. Corey. "Inhibition of human telomerase by 2′-O-methyl-RNA." Proceedings of the National Academy of Sciences 95, no. 20 (1998): 11549-11554.

    Why choose Hongene?

    Trusted Partner in Nucleic Acid

    Enjoy enterprise‑grade quality even with small batch orders.

    Integrated Supply & Commercial Scale

    With nearly 30 years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.

    Proprietary Technology & IP

    Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.

    Rigorous Quality

    We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.

    Manufacturing Scalability

    Hongene operates a 1.67-million-square-foot oligonucleotide manufacturing facility featuring advanced equipment, including multiple OligoPilot™ and OligoProcess™ synthesizers ranging from 10 to 1,800 mmol. Its 48 flexible production lines enable seamless, one-stop scale-up of API production from gram-level quantities to metric tons, achieving purity of ≥98% while supporting compliance with NMPA, FDA, and EMA regulatory requirements.

    Global Business Network

    Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.

    Global Business Distribution
    40+
    Countries & Regions
    ≈3000
    Global Clients
    54000L+
    Annual NTP Production
    58t+
    Annual Amidites Production

    Ask us anything!

    Back to top